Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Glenmark Pharmaceuticals Ltd    GLENMARK   INE935A01035

GLENMARK PHARMACEUTICALS LTD

(GLENMARK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
445.7(c) 453.3(c) 446.55(c) 440.85(c) 432.85 Last
489 116 968 731 738 913 783 574 719 816 Volume
-1.25% +1.71% -1.49% -1.28% -1.81% Change
More quotes
Financials (INR)
Sales 2020 109 B
EBIT 2020 14 690 M
Net income 2020 8 913 M
Debt 2020 36 715 M
Yield 2020 0,53%
Sales 2021 121 B
EBIT 2021 16 469 M
Net income 2021 10 496 M
Debt 2021 33 576 M
Yield 2021 0,56%
P/E ratio 2020 13,7x
P/E ratio 2021 11,6x
EV / Sales2020 1,46x
EV / Sales2021 1,28x
Capitalization 122 B
More Financials
Company
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven... 
Sector
Pharmaceuticals
Calendar
08/13Earnings Release
More about the company
Surperformance© ratings of Glenmark Pharmaceuticals L
Trading Rating : Investor Rating :
More Ratings
Latest news on GLENMARK PHARMACEUTICALS L
07/12GLENMARK PHARMACEUTICALS : Fitch Affirms Glenmark Pharmaceuticals at 'BB' Outloo..
AQ
06/25GLENMARK PHARMACEUTICALS : to partner with Novartis to promote, commercialize an..
AQ
06/25GLENMARK PHARMACEUTICALS : signs deal with Novartis over distribution in Brazil
AQ
06/24GLENMARK PHARMACEUTICALS : Novartis Partner to Distribute COPD Products in Brazi..
DJ
06/24GLENMARK PHARMACEUTICALS : Pharma says USFDA has issued CRL for Ryaltris
AQ
05/30GLENMARK PHARMACEUTICALS : consolidated revenue rises 12.44% to Rs. 25,634.74 Mn..
AQ
05/24GLENMARK PHARMACEUTICALS LTD : annual earnings release
05/22GLENMARK PHARMACEUTICALS : launches new diabetes medicine
AQ
05/21GLENMARK PHARMACEUTICALS : launches new diabetes medicine
AQ
05/15GLENMARK PHARMACEUTICALS : Pharma gets USFDA nod for acid reflux medication
AQ
More news
Analyst Recommendations on GLENMARK PHARMACEUTICALS L
More recommendations
Sector news : Generic Pharmaceuticals
05:45aJOHNSON & JOHNSON : Faces Key Test in Defense Against Talc-Safety Lawsuits
DJ
07/19CELGENE : Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease
DJ
07/19ALLERGAN : Form 8.3 -
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19JOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
More sector news : Generic Pharmaceuticals
Chart GLENMARK PHARMACEUTICALS LTD
Duration : Period :
Glenmark Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLENMARK PHARMACEUTICALS L
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 582,29  INR
Last Close Price 432,85  INR
Spread / Highest target 100%
Spread / Average Target 34,5%
Spread / Lowest Target 10,9%
EPS Revisions
Managers
NameTitle
Glenn Mario Saldanha Chairman, Chief Executive Officer & MD
Kanish Malik Co-President & Head-Global Operations
Kurt Stoeckli Co-President & Chief Scientific Officer
V. S. Mani President, CFO & Executive Director
Jayaram Philkana Co-President & Chief Human Resources Officer
Sector and Competitors